API | sebacoyl dinalbuphine ester

sebacoyl dinalbuphine ester (Naldebain) Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Dinalbuphine sebacate (DNS), also known as nalbuphine sebacate or as sebacoyl dinalbuphine ester (SDE) and sold under the brand name Naldebain, is a non-controlled opioid analgesic which is used as a 7-day long-acting injection in the treatment of moderate to severe postoperative pain. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action:
- Mu-type opioid receptor (Homo sapiens) ^UniProt
- Kappa-type opioid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

sebacoyl dinalbuphine ester

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Pain

Experimental Indications - Clinical Trial Phases 1-4 (4)

Analgesia (Phase 2/Phase 3)

Cesarean Section (Phase 2)

Pain (Phase 2/Phase 3)

Pain, Postoperative (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue